Multimodality Treatment for Locally Advanced Gastric Adenocarcinoma

被引：0
作者：
Srikumar, Thejal [1 ]
Sundar, Raghav [2 ,3 ]
机构：
[1] Yale Univ, Sch Med, 333 Cedar St, New Haven, CT USA
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, 1E Kent Ridge Rd, Singapore 119228, Singapore
[3] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore
来源：
SURGICAL CLINICS OF NORTH AMERICA | 2025年 / 105卷 / 01期
关键词：
Gastric cancer; Multimodality; Perioperative; Chemotherapy; Chemoradiation; PHASE-III TRIAL; CLINICAL-PRACTICE GUIDELINE; ESOPHAGEAL CANCER; PERIOPERATIVE CHEMOTHERAPY; ESOPHAGOGASTRIC JUNCTION; OPEN-LABEL; ADJUVANT CHEMOTHERAPY; SURGICAL RESECTION; CHEMORADIOTHERAPY; SURGERY;
D O I：
10.1016/j.suc.2024.06.007
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：75 / 94
页数：20
相关论文
共 58 条
  • [1] Gastric Cancer, Version 2.2022
    Ajani, Jaffer A.
    D'Amico, Thomas A.
    Bentrem, David J.
    Chao, Joseph
    Cooke, David
    Corvera, Carlos
    Das, Prajnan
    Enzinger, Peter C.
    Enzler, Thomas
    Fanta, Paul
    Farjah, Farhood
    Gerdes, Hans
    Gibson, Michael K.
    Hochwald, Steven
    Hofstetter, Wayne L.
    Ilson, David H.
    Keswani, Rajesh N.
    Kim, Sunnie
    Kleinberg, Lawrence R.
    Klempner, Samuel J.
    Lacy, Jill
    Ly, Quan P.
    Matkowskyj, Kristina A.
    McNamara, Michael
    Mulcahy, Mary F.
    Outlaw, Darryl
    Park, Haeseong
    Perry, Kyle A.
    Pimiento, Jose
    Poultsides, George A.
    Reznik, Scott
    Roses, Robert E.
    Strong, Vivian E.
    Su, Stacey
    Wang, Hanlin L.
    Wiesner, Georgia
    Willett, Christopher G.
    Yakoub, Danny
    Yoon, Harry
    McMillian, Nicole
    Pluchino, Lenora A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02): : 167 - 192
  • [2] Al-Batran SE, 2022, J CLIN ONCOL, V40
  • [3] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    [J]. LANCET, 2019, 393 (10184) : 1948 - 1957
  • [4] The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI
    Al-Batran, Salah-Eddin
    Goetze, Thorsten O.
    Mueller, Daniel W.
    Vogel, Arndt
    Winkler, Michael
    Lorenzen, Sylvie
    Novotny, Alexander
    Pauligk, Claudia
    Homann, Nils
    Jungbluth, Thomas
    Reissfelder, Christoph
    Caca, Karel
    Retter, Steffen
    Horndasch, Eva
    Gumpp, Julia
    Bolling, Claus
    Fuchs, Karl-Hermann
    Blau, Wolfgang
    Padberg, Winfried
    Pohl, Michael
    Wunsch, Andreas
    Michl, Patrick
    Mannes, Frank
    Schwarzbach, Matthias
    Schmalenberg, Harald
    Hohaus, Michael
    Scholz, Christian
    Benckert, Christoph
    Knorrenschild, Jorge Riera
    Kanngiesser, Veit
    Zander, Thomas
    Alakus, Hakan
    Hofheinz, Ralf-Dieter
    Roedel, Claus
    Shah, Manish A.
    Sasako, Mitsuru
    Lorenz, Dietmar
    Izbicki, Jakob
    Bechstein, Wolf O.
    Lang, Hauke
    Moenig, Stefan P.
    [J]. BMC CANCER, 2017, 17
  • [5] Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer The AIO-FLOT3 Trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Illerhaus, Gerald
    Martens, Uwe M.
    Stoehlmacher, Jan
    Schmalenberg, Harald
    Luley, Kim B.
    Prasnikar, Nicole
    Egger, Matthias
    Probst, Stephan
    Messmann, Helmut
    Moehler, Markus
    Fischbach, Wolfgang
    Hartmann, Joerg T.
    Mayer, Frank
    Hoeffkes, Heinz-Gert
    Koenigsmann, Michael
    Arnold, Dirk
    Kraus, Thomas W.
    Grimm, Kersten
    Berkhoff, Stefan
    Post, Stefan
    Jager, Elke
    Bechstein, Wolf
    Ronellenfitsch, Ulrich
    Moenig, Stefan
    Hofheinz, Ralf D.
    [J]. JAMA ONCOLOGY, 2017, 3 (09) : 1237 - 1244
  • [6] Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
    Andre, Thierry
    Tougeron, David
    Piessen, Guillaume
    de la Fouchardiere, Christelle
    Louvet, Christophe
    Adenis, Antoine
    Jary, Marine
    Tournigand, Christophe
    Aparicio, Thomas
    Desrame, Jerome
    Lievre, Astrid
    Garcia-Larnicol, Marie-Line
    Pudlarz, Thomas
    Cohen, Romain
    Memmi, Salome
    Vernerey, Dewi
    Henriques, Julie
    Lefevre, Jeremie H.
    Svrcek, Magali
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 255 - +
  • [7] Global burden of oesophageal and gastric cancer by histology and subsite in 2018
    Arnold, Melina
    Ferlay, Jacques
    Henegouwen, Mark I. van Berge
    Soerjomataram, Isabelle
    [J]. GUT, 2020, 69 (09) : 1564 - 1571
  • [8] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Bang, Yung-Jue
    Kim, Young-Woo
    Yang, Han-Kwang
    Chung, Hyun Cheol
    Park, Young-Kyu
    Lee, Kyung Hee
    Lee, Keun-Wook
    Kim, Yong Ho
    Noh, Sang-Ik
    Cho, Jae Yong
    Mok, Young Jae
    Kim, Yeul Hong
    Ji, Jiafu
    Yeh, Ta-Sen
    Button, Peter
    Sirzen, Florin
    Noh, Sung Hoon
    [J]. LANCET, 2012, 379 (9813) : 315 - 321
  • [9] Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
    Cats, Annemieke
    Jansen, Edwin P. M.
    van Grieken, Nicole C. T.
    Sikorska, Karolina
    Lind, Pehr
    Nordsmark, Marianne
    Kranenbarg, Elma Meershoek-Klein
    Boot, Henk
    Trip, Anouk K.
    Swellengrebel, H. A. Maurits
    van Laarhoven, Hanneke W. M.
    Putter, Hein
    van Sandick, Johanna W.
    Henegouwen, Mark I. van Berge
    Hartgrink, Henk H.
    van Tinteren, Harm
    van de Velde, Cornelis J. H.
    Verheij, Marcel
    [J]. LANCET ONCOLOGY, 2018, 19 (05) : 616 - 628
  • [10] Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
    Conroy, Thierry
    Galais, Marie-Pierre
    Raoul, Jean-Luc
    Bouche, Olivier
    Gourgou-Bourgade, Sophie
    Douillard, Jean-Yves
    Etienne, Pierre-Luc
    Boige, Valerie
    Martel-Lafay, Isabelle
    Michel, Pierre
    Llacer-Moscardo, Carmen
    Francois, Eric
    Crehange, Gilles
    Ben Abdelghani, Meher
    Juzyna, Beata
    Bedenne, Laurent
    Adenis, Antoine
    [J]. LANCET ONCOLOGY, 2014, 15 (03) : 305 - 314
123456